Post-hoc analysis of the ADAPT study has also revealed a sustained effect of efgartigimod across repeated treatment cycles, demonstrating its efficacity as a long-term treatment option [230]

INGREDIENTS: Water, Dipropylene Glycol, Glycerin, Niacinamide, Octyldodecanol, Helianthus Annuus (Sunflower) Seed Oil, Butylene Glycol, Trehalose, Pentylene Glycol, 1,2-Hexanediol, Eriobotrya Japonica Leaf Extract, Coptis Japonica Root Extract, Mentha Viridis (Spearmint) Extract, Sodium Hyaluronate, Theobroma Cacao (Cocoa) Extract, Centella Asiatica Leaf Extract, Argania Spinosa Kernel Oil, Sesamum Indicum (Sesame) Seed Oil, Chitosan, Serenoa Serrulata Fruit Extract, Caprylyl Methicone, Panthenol, Polymethylsilsesquioxane, Propanediol, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Cetearyl Olivate, Polyglyceryl-10 Behenate/Eicosadioate, Ammonium Acryloyldimethyltaurate/VP Copolymer, Sorbitan Olivate, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Tromethamine, Ethylhexylglycerin, Sorbitan Isostearate, Adenosine, Palmitic Acid, Hydrogenated Lecithin, Glutathione, Phosphatidylcholine, Polyglyceryl-10 Laurate, Dilauryl Thiodipropionate, Pentaerythrityl Tetra-di-t-butyl Hydroxyhydrocinnamate, Sodium Phytate, Allantoin, Madecassoside, Lecithin, Cellulose, Sodium Phosphate, Polyglutamic Acid, Dextrin, Asiaticoside, Cysteine, Tocopherol, 3-O-Ethyl Ascorbic Acid, Arbutin, Bisabolol, sh-Oligopeptide-1, sh-Oligopeptide-2, sh-Polypeptide-1, sh-Polypeptide-10, sh-Polypeptide-11, sh-Polypeptide-3, sh-Polypeptide-59, sh-Polypeptide-9, Cholesterol, Ascorbic Acid, Beta-Sitosterol, Ascorbyl Glucoside, Ceramide NP, Xanthan Gum, C12-16 Alcohol

Gallbladder-related adverse events, including cholelithiasis and cholecystitis, have been reported more frequently in patients receiving semaglutide compared to placebo in clinical trials, with an incidence of approximately two to three percent
10.1016/j.arcmed.2007.12.007 Arch